about
Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionMechanisms of Hepatitis C Viral Resistance to Direct Acting AntiviralsVirologic Tools for HCV Drug Resistance TestingNew era for management of chronic hepatitis C virus using direct antiviral agents: A reviewPrevention of portal hypertension: from variceal development to clinical decompensationSeed Sequence-Matched Controls Reveal Limitations of Small Interfering RNA Knockdown in Functional and Structural Studies of Hepatitis C Virus NS5A-MOBKL1B InteractionEnhancing our understanding of current therapies for hepatitis C virus (HCV)Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agentsPhysicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.New Therapies for Hepatitis C Virus Infection.Therapeutic Potential of Spirooxindoles as Antiviral AgentsHepatitis C virus NS5A inhibitors and drug resistance mutations.Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approachPhysical and functional interaction between hepatitis C virus NS5A protein and ovarian tumor protein deubiquitinase 7B.Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia.Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.Phosphorylation of Serine 235 of the Hepatitis C Virus Non-Structural Protein NS5A by Multiple KinasesCritical role of Casein kinase 2 in hepatitis C NS5A-mediated inhibition of Kv2.1 K(+) channel function.Interferon-inducible protein SCOTIN interferes with HCV replication through the autolysosomal degradation of NS5A.ISG12a Restricts Hepatitis C Virus Infection through the Ubiquitination-Dependent Degradation Pathway.Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents.Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.Approaches to hepatitis C treatment and cure using NS5A inhibitorsOptimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.Emerging treatments for hepatitis C.Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection.Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection.Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.New treatments for chronic hepatitis C: an overview for paediatricians.Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.Hepatitis C virus drug resistance-associated substitutions: State of the art summary.What does the pharmacological future of treating chronic hepatitis C look like?Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature.Daclatasvir for the treatment of chronic hepatitis C.Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection.Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Doses of Pibrentasvir in a First-in-Human Study.
P2860
Q26746563-3685F83E-18F9-40A7-ABCB-D0F7D08A71F0Q26773321-6A0ACADF-D7D5-428E-B32A-433ABCA1B75AQ26774374-F302782D-02C6-4097-9776-3086D20A4A95Q26800050-BE814C48-6DC3-460D-B6BB-D0D1BDC72405Q26865665-A7B026E8-6C0B-4014-9CB4-CF2F649F0926Q27684710-5BD8EB96-D5C6-4DD0-AAD4-060A00AC1D23Q28085718-E6800173-FE5B-49CF-89A9-DAC0DFD77BEDQ28538891-ACC42674-2886-4FB7-BCEF-3F3B207F6ACAQ30435394-3DDEBECD-FB09-4434-8191-7F6C3B30D7F7Q33560181-FFE2794A-044D-4B96-83DD-8E37CBED9BA4Q33637160-41CBD6D0-77C3-4F40-A1FE-6D4A99A5CA83Q34411617-606C8513-6989-4693-8710-43CA728F09D9Q34481846-EECB3F8C-3719-4721-8EEF-7C025D7A7D38Q35501190-C2FE6AD7-0CBC-4A0A-AD88-7686765D77FFQ35607835-3ADD9131-8CE6-4DA6-A802-221D96E219A6Q35674938-B13973AC-6285-4FDF-856F-E6D6B1C44D87Q35735285-12BC3945-C8C8-4620-B6A2-BA8759598A3EQ35774186-C49F7C97-2405-4D91-8C96-E7A9CDCD6FFDQ36173242-8337032D-DA92-488D-819C-6F5B12F3F31BQ36201245-E271019D-FDD7-462F-815B-CDCC70AE4E9BQ36373257-B5024C48-F413-4938-B8D2-FE7D09100F81Q36582285-E66AB17F-4C5B-4124-B2B2-4AB0958FF9AEQ37093500-480B9C4F-AEE6-4C34-84F6-C945EA10C341Q37310564-52C14333-A742-456A-88CD-DDFFEB647A0EQ37426527-34767174-3306-46F1-A252-E0BFC303B83AQ37630422-4A721E49-0361-439E-BBFD-9D88A2102D4CQ37682673-A4C12D1A-1FCC-4B4C-BE58-0347C9F775FCQ38150403-75853801-922C-4788-A73C-835AF20E1EB5Q38193198-9A74A207-A48E-4F0C-A97D-DB23CEA99E80Q38249065-176E5554-8C7B-43FB-818A-E3613D6A7D3EQ38262922-91BA20D3-5BC5-4CA4-B45B-12E9DFA30F10Q38282842-66944B46-B414-408F-820F-553CAF6969D0Q38516135-AA1DB2F3-60A0-4B30-9BD3-798867FC1B37Q38530211-A6C61062-5C72-41AE-90E9-094D799B57AEQ38533619-9271E71C-F6F6-439E-820A-23E5531989ABQ38569681-36F0BDC9-4C85-4682-A071-F93E503541FFQ38581478-6F526949-27B6-4A1C-8202-391A3889A268Q38628237-084F2127-66F7-4260-9B38-7F54DADA9988Q38793356-EC337786-13E5-4290-9E25-421F47E595ACQ38808556-90888BC2-2119-40CE-AA1D-902613A2D483
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
NS5A inhibitors in the treatment of hepatitis C.
@en
type
label
NS5A inhibitors in the treatment of hepatitis C.
@en
prefLabel
NS5A inhibitors in the treatment of hepatitis C.
@en
P1476
NS5A inhibitors in the treatment of hepatitis C.
@en
P2093
Jean-Michel Pawlotsky
P304
P356
10.1016/J.JHEP.2013.03.030
P577
2013-04-06T00:00:00Z